PRIVACY ANALYTICS a QuintileslMS company ..._ SANOFl v CASE STUDY OVERVIEW Sanofi has a number of initiatives to share clinical trial data with the research commu­ nity for secondary purposes. Maximizing the utility of clinical trial participant data provides opportuni­ ties to conduct further research, help ad­ vance medical sci­ ence and improve patient care. Sanofi is not alone in this drive to share clinical trial data. There is a growing movement to increase the sharing of clinical trial data by research­ ers and manufactur­ ers. As manufacturers start to make individ­ ual participant data (IPD) from their clinical trials available, privacy concerns must be addressed. A Scalable, Risk-based Approach to De-identifying Clinical Trial Data: A Case S

Join for free to read